The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Targeted-protein Degradation Therapeutics Market Research Report 2025
Synopsis
Targeted protein degradation (TPD) has surfaced as a novel and innovative chemical tool and therapeutic modality. By co-opting protein degradation pathways, TPD facilitates complete removal of the protein molecules from within or outside the cell. While the pioneering Proteolysis-Targeting Chimera (PROTAC) technology and molecular glues hijack the ubiquitin-proteasome system, newer modalities co-opt autophagy or the endo-lysosomal pathway.
The global Targeted-protein Degradation Therapeutics market was valued at US$ 1132 million in 2023 and is anticipated to reach US$ 1821.4 million by 2030, witnessing a CAGR of 6.3% during the forecast period 2024-2030.
The Protein Degradation Therapy market has gained momentum as a promising approach in drug development. This innovative strategy aims to target disease-causing proteins by facilitating their degradation within cells. Proteins that contribute to diseases like cancer and neurodegenerative disorders can be selectively broken down using small molecules known as proteolysis-targeting chimeras (PROTACs) or other protein degraders. This approach offers advantages over traditional inhibition methods, potentially leading to more effective treatments with reduced side effects. As researchers delve into protein-protein interactions and cellular mechanisms, the Protein Degradation Therapy market is expanding, presenting opportunities to address previously challenging diseases and advance precision medicine. Clinical progress and continued research in this field are expected to shape the future of therapeutic interventions.
This report aims to provide a comprehensive presentation of the global market for Targeted-protein Degradation Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted-protein Degradation Therapeutics.
Report Scope
The Targeted-protein Degradation Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Targeted-protein Degradation Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Targeted-protein Degradation Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Arvinas
Nurix Therapeutics
Kymera Therapeutics
C4 Therapeutics
Segment by Type
ARV-110
ARV-471
Other
Segment by Application
Cancer
Neuroscience
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Targeted-protein Degradation Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Targeted protein degradation (TPD) has surfaced as a novel and innovative chemical tool and therapeutic modality. By co-opting protein degradation pathways, TPD facilitates complete removal of the protein molecules from within or outside the cell. While the pioneering Proteolysis-Targeting Chimera (PROTAC) technology and molecular glues hijack the ubiquitin-proteasome system, newer modalities co-opt autophagy or the endo-lysosomal pathway.
The global Targeted-protein Degradation Therapeutics market was valued at US$ 1132 million in 2023 and is anticipated to reach US$ 1821.4 million by 2030, witnessing a CAGR of 6.3% during the forecast period 2024-2030.
The Protein Degradation Therapy market has gained momentum as a promising approach in drug development. This innovative strategy aims to target disease-causing proteins by facilitating their degradation within cells. Proteins that contribute to diseases like cancer and neurodegenerative disorders can be selectively broken down using small molecules known as proteolysis-targeting chimeras (PROTACs) or other protein degraders. This approach offers advantages over traditional inhibition methods, potentially leading to more effective treatments with reduced side effects. As researchers delve into protein-protein interactions and cellular mechanisms, the Protein Degradation Therapy market is expanding, presenting opportunities to address previously challenging diseases and advance precision medicine. Clinical progress and continued research in this field are expected to shape the future of therapeutic interventions.
This report aims to provide a comprehensive presentation of the global market for Targeted-protein Degradation Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted-protein Degradation Therapeutics.
Report Scope
The Targeted-protein Degradation Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Targeted-protein Degradation Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Targeted-protein Degradation Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Arvinas
Nurix Therapeutics
Kymera Therapeutics
C4 Therapeutics
Segment by Type
ARV-110
ARV-471
Other
Segment by Application
Cancer
Neuroscience
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Targeted-protein Degradation Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Targeted-protein Degradation Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 ARV-110
1.2.3 ARV-471
1.2.4 Other
1.3 Market by Application
1.3.1 Global Targeted-protein Degradation Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Cancer
1.3.3 Neuroscience
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Targeted-protein Degradation Therapeutics Market Perspective (2019-2030)
2.2 Targeted-protein Degradation Therapeutics Growth Trends by Region
2.2.1 Global Targeted-protein Degradation Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Targeted-protein Degradation Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Targeted-protein Degradation Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Targeted-protein Degradation Therapeutics Market Dynamics
2.3.1 Targeted-protein Degradation Therapeutics Industry Trends
2.3.2 Targeted-protein Degradation Therapeutics Market Drivers
2.3.3 Targeted-protein Degradation Therapeutics Market Challenges
2.3.4 Targeted-protein Degradation Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Targeted-protein Degradation Therapeutics Players by Revenue
3.1.1 Global Top Targeted-protein Degradation Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Targeted-protein Degradation Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Targeted-protein Degradation Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Targeted-protein Degradation Therapeutics Revenue
3.4 Global Targeted-protein Degradation Therapeutics Market Concentration Ratio
3.4.1 Global Targeted-protein Degradation Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Targeted-protein Degradation Therapeutics Revenue in 2023
3.5 Targeted-protein Degradation Therapeutics Key Players Head office and Area Served
3.6 Key Players Targeted-protein Degradation Therapeutics Product Solution and Service
3.7 Date of Enter into Targeted-protein Degradation Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Targeted-protein Degradation Therapeutics Breakdown Data by Type
4.1 Global Targeted-protein Degradation Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Targeted-protein Degradation Therapeutics Forecasted Market Size by Type (2025-2030)
5 Targeted-protein Degradation Therapeutics Breakdown Data by Application
5.1 Global Targeted-protein Degradation Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Targeted-protein Degradation Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Targeted-protein Degradation Therapeutics Market Size (2019-2030)
6.2 North America Targeted-protein Degradation Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Targeted-protein Degradation Therapeutics Market Size by Country (2019-2024)
6.4 North America Targeted-protein Degradation Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Targeted-protein Degradation Therapeutics Market Size (2019-2030)
7.2 Europe Targeted-protein Degradation Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Targeted-protein Degradation Therapeutics Market Size by Country (2019-2024)
7.4 Europe Targeted-protein Degradation Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Targeted-protein Degradation Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Targeted-protein Degradation Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Targeted-protein Degradation Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Targeted-protein Degradation Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Targeted-protein Degradation Therapeutics Market Size (2019-2030)
9.2 Latin America Targeted-protein Degradation Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Targeted-protein Degradation Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Targeted-protein Degradation Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Targeted-protein Degradation Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Targeted-protein Degradation Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Targeted-protein Degradation Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Targeted-protein Degradation Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Arvinas
11.1.1 Arvinas Company Detail
11.1.2 Arvinas Business Overview
11.1.3 Arvinas Targeted-protein Degradation Therapeutics Introduction
11.1.4 Arvinas Revenue in Targeted-protein Degradation Therapeutics Business (2019-2024)
11.1.5 Arvinas Recent Development
11.2 Nurix Therapeutics
11.2.1 Nurix Therapeutics Company Detail
11.2.2 Nurix Therapeutics Business Overview
11.2.3 Nurix Therapeutics Targeted-protein Degradation Therapeutics Introduction
11.2.4 Nurix Therapeutics Revenue in Targeted-protein Degradation Therapeutics Business (2019-2024)
11.2.5 Nurix Therapeutics Recent Development
11.3 Kymera Therapeutics
11.3.1 Kymera Therapeutics Company Detail
11.3.2 Kymera Therapeutics Business Overview
11.3.3 Kymera Therapeutics Targeted-protein Degradation Therapeutics Introduction
11.3.4 Kymera Therapeutics Revenue in Targeted-protein Degradation Therapeutics Business (2019-2024)
11.3.5 Kymera Therapeutics Recent Development
11.4 C4 Therapeutics
11.4.1 C4 Therapeutics Company Detail
11.4.2 C4 Therapeutics Business Overview
11.4.3 C4 Therapeutics Targeted-protein Degradation Therapeutics Introduction
11.4.4 C4 Therapeutics Revenue in Targeted-protein Degradation Therapeutics Business (2019-2024)
11.4.5 C4 Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
